Skip to main content
. 2018 Mar 21;9:127. doi: 10.3389/fneur.2018.00127

Figure 3.

Figure 3

Calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationship between methylation and progression-free survival benefit from temozolomide (TMZ)-containing or TMZ-free therapy in overall glioblastoma patients (methylated vs. unmethylated patients).